Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engineered immune cells tested as new weapon against Tough-to-Treat skin cancer

NCT ID NCT05470283

Summary

This is an early-stage study to find a safe dose of a new cell therapy called OBX-115, given with a pill called acetazolamide. It is for adults with metastatic melanoma that has stopped responding to standard immunotherapies. The main goals are to check the safety of the treatment and see if it can help shrink tumors.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.